Effect of miltefosine lipid nanocapsule formulations (MFS-LNCs) on hepatic granulomas size in μm as compared with control groups.
- Maha M. Eissa (827785)
- Riham M. El-Moslemany (827786)
- Alyaa A. Ramadan (827787)
- Eglal I. Amer (827788)
- Mervat Z. El-Azzouni (827789)
- Labiba K. El-Khordagui (827790)
Publication date
November 2015
DOIAbstract
<p>* F test (ANOVA), % R<sub>1</sub>: % reduction in each of the study groups relative to infected control %R<sub>2</sub>: % reduction in each of the study groups relative to miltefosine solution control</p><p><sup>a:</sup> significant with infected untreated control</p><p><sup>b:</sup> significant with MFS solution control</p><p><sup>c:</sup> significant with group I</p><p><sup>d:</sup> significant with group II</p><p><sup>e:</sup> significant with group III</p><p><sup>f:</sup> significant with group IV</p><p><sup>g:</sup> significant with group V</p><p>F* = 110.924 (p<0.001).</p
Add to ORKG